Menopausal hormone therapy and risk of oesophageal adenocarcinoma in a population-based cohort study

2021 ◽  
Author(s):  
Shao-Hua Xie ◽  
Giola Santoni ◽  
Jesper Lagergren
Keyword(s):  
Cohort Study ◽  
Hormone Therapy ◽  
Population Based ◽  
Menopausal Hormone Therapy ◽  
Oesophageal Adenocarcinoma

scholarly journals Menopausal hormone therapy and colorectal cancer: a linkage between nationwide registries in Norway

BMJ Open ◽  
2017 ◽  
Vol 7 (11) ◽  
pp. e017639 ◽  
Author(s):  
Edoardo Botteri ◽  
Nathalie C Støer ◽  
Solveig Sakshaug ◽  
Sidsel Graff-Iversen ◽  
Siri Vangen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Hormone Therapy ◽  
Population Based ◽  
Menopausal Hormone Therapy ◽  
Anatomic Site ◽  
Oral Formulations ◽  
Norwegian Population ◽  
Progestin Therapy ◽  
Rate Ratios

ObjectivesWith the present study, we aimed to investigate the association between menopausal hormone therapy (HT) and risk of colorectal cancer (CRC).SettingCohort study based on the linkage of Norwegian population-based registries.ParticipantsWe selected 466822 Norwegian women, aged 55–79, alive and residing in Norway as of 1 January 2004, and we followed them from 2004 to 2008. Each woman contributed person-years at risk as non-user, current user and/or past HT user.Outcome measuresThe outcome of interest was adenocarcinoma of the colorectal tract, overall, by anatomic site and stage at diagnosis. Incidence rate ratios (RRs) with 95% CIs were estimated by Poisson regression and were used to evaluate the association between HT and CRC incidence.ResultsDuring the median follow-up of 4.8 years, 138 655 (30%) women received HT and 3799 (0.8%) incident CRCs occurred. Current, but not past, use of HT was associated with a lower risk of CRC (RR 0.88; 95% CI 0.80 to 0.98). RRs for localised, regionally advanced and metastatic CRC were 1.13 (95% CI 0.91 to 1.41), 0.81 (95% CI 0.70 to 0.94) and 0.79 (95% CI 0.62 to 1.00), respectively. RRs for current use of oestrogen therapy (ET) were 0.91 (95% CI 0.80 to 1.04) while RR for current use of combined oestrogen–progestin therapy (EPT) was 0.85 (95% CI 0.70 to 1.03), as compared with no use of HT. The same figures for ET and EPT in oral formulations were 0.83 (95% CI 0.68 to 1.03) and 0.86 (95% CI 0.71 to 1.05), respectively.ConclusionsIn our nationwide cohort study, HT use lowered the risk of CRC, specifically the most advanced CRC.

scholarly journals Menopausal hormone therapy and biliary tract cancer: a population-based matched cohort study in Sweden

2019 ◽  
Vol 58 (3) ◽  
pp. 290-295 ◽  
Author(s):  
C. Kilander ◽  
J. Lagergren ◽  
P. Konings ◽  
O. Sadr-Azodi ◽  
N. Brusselaers
Keyword(s):  
Cohort Study ◽  
Hormone Therapy ◽  
Biliary Tract ◽  
Biliary Tract Cancer ◽  
Population Based ◽  
Menopausal Hormone Therapy ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Tract Cancer

Menopausal hormone therapy and risk of melanoma: a population‐based cohort study

2021 ◽  
Author(s):  
N.C. Støer ◽  
E. Botteri ◽  
M. Busund ◽  
R. Ghiasvand ◽  
S. Vangen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hormone Therapy ◽  
Population Based ◽  
Menopausal Hormone Therapy

scholarly journals The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ji Hyung Nam ◽  
Sung-In Jang ◽  
Hyun Soo Park ◽  
Jae Hak Kim ◽  
Jun Kyu Lee ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hormone Therapy ◽  
Dose Response ◽  
Population Based ◽  
Menopausal Hormone Therapy ◽  
Response Relationship ◽  
Dose Response Relationship ◽  
Gi Cancer ◽  
Kaplan Meier ◽  
Gi Cancers

Abstract Background The effect of menopausal hormone therapy (MHT) on gastrointestinal (GI) cancers is controversial, and no research has been conducted in the East. This study investigates the association between MHT and GI cancer risks in South Korea. Methods A prescription-based cohort study was conducted using the NHIS Sample Cohort (2002–2013) of Korea. We used 1:5 propensity score matching, and 22,577 MHT users and 111,113 non-users were selected. Kaplan–Meier survival curves with log-rank tests were used. Cox proportional hazard models were used to estimate hazard ratios (HR) with 95% confidence intervals (CI). Landmark analysis was used to determine dose–response relationship. Results The median follow-up was 79.6 of months. Kaplan–Meier survival curve showed less frequent GI cancer diagnoses in MHT users compared to non-users (0.13 vs. 0.16 per 100,000 person-years). Menopausal hormone therapy was associated with decreased incidence of GI cancer (HR = 0.809, 95%CI = 0.691–0.946) and colorectal cancer (CRC) (HR = 0.757, 95%CI = 0.577–0.995). Gastric cancer (GC) incidence showed marginal significance (HR = 0.787, 95%CI = 0.605–1.023). The mortality from GI cancer was lower in MHT users than in non-users (HR = 0.737, 95%CI = 0.547–0.993). The relationship between MHT and GI cancer was stronger with increasing MHT dose in terms of both incidence (Ptrend = 0.0002) and mortality (Ptrend = 0.0064). Conclusions The association between MHT use and reduced risks of GI cancers was attributed to CRC and GC and showed a dose–response relationship in a population-based cohort study.

scholarly journals 473 Menopausal Hormone Therapy and Risk of Cholecystomy in the French E3N Prospective Cohort Study

2012 ◽  
Vol 142 (5) ◽  
pp. S-99
Author(s):  
Antoine Racine ◽  
Anne Bijon ◽  
Sylvie Mesrine ◽  
Françoise Clavel-Chapelon ◽  
Franck Carbonnel ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hormone Therapy ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Menopausal Hormone Therapy

scholarly journals No association between colon cancer and adenocarcinoma of the oesophagus in a population based cohort study in Sweden

Gut ◽  
1999 ◽  
Vol 44 (6) ◽  
pp. 819-821 ◽  
Author(s):  
J Lagergren ◽  
O Nyren
Keyword(s):  
Colon Cancer ◽  
Cohort Study ◽  
Relative Risk ◽  
Population Based ◽  
Oesophageal Adenocarcinoma ◽  
Expected Number ◽  
Colonic Neoplasia ◽  
Barrett's Metaplasia ◽  
Barrett’S Metaplasia

BACKGROUNDPrevious reports have indicated an association between Barrett’s metaplasia or adenocarcinoma of the oesophagus and colonic neoplasia, but the findings have been inconsistent. If true, such an association suggests common causal mechanisms.AIMSTo test the hypothesis of an association between Barrett’s metaplasia or adenocarcinoma of the oesophagus and colonic neoplasia.METHODSA population based, retrospective cohort study was performed on all Swedish patients with colon cancer diagnosed between 1958 and 1992. 538 500 person years at risk were reviewed among the 118 030 patients in the cohort (average follow up 4.6 years, median 2.1 years). The standardised incidence ratio (SIR), the ratio of the observed to the expected number of incident oesophageal adenocarcinomas, was used as a measure of relative risk. The expected number was derived from the entire Swedish population.RESULTSEleven oesophageal adenocarcinomas were found during follow up in the cohort, as against 9.5 expected (SIR=1.2; 95% confidence interval 0.6–2.1). Analysis by latency intervals after diagnosis of colon cancer showed no trend towards increasing or decreasing risk over time. There were no important sex differences in relative risk.CONCLUSIONSResults provide no support for a common link between colon cancer and oesophageal adenocarcinoma. Although the direct relation between colon cancer and Barrett’s oesophagus was not looked at, a search for common aetiological factors or genetic defects may not be fruitful. Screening for colonic neoplasia among patients with malignant or premalignant oesophageal mucosa, or vice versa, may not be warranted.

Sign in / Sign up

Export Citation Format

Share Document